A carregar...
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy (ACT) based on ex vivo expanded peripheral CTLs, tumor infiltrating lymphocytes (TILs), gene-engineered TCR- and chimeric antigen...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6658873/ https://ncbi.nlm.nih.gov/pubmed/31379815 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.01574 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|